Journal article
Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in Girls Living With HIV
Abstract
We evaluated quadrivalent human papillomavirus vaccine seroresponses among 35 girls living with HIV (9-13 years of ages) and compared with data on girls without HIV, as part of a subgroup analysis. The quadrivalent human papillomavirus vaccine was safe and well tolerated. However, antibody response was significantly lower in girls living with HIV relative to girls without HIV. HIV virologic suppression predicted better antibody response.
Authors
Brophy J; Bitnun A; Alimenti A; Lapointe N; Samson L; Read S; Karatzios C; Dobson S; Moses E; Blitz S
Journal
The Pediatric Infectious Disease Journal, Vol. 37, No. 6, pp. 595–597
Publisher
Wolters Kluwer
Publication Date
6 2018
DOI
10.1097/inf.0000000000001874
ISSN
0891-3668